InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,064.20
(
0.91%
)
US TECH 100
17,173.20
(
1.85%
)
Dow Jones
38,225.66
(
0.85%
)
Brent Oil
83.81
(
0.21%
)
Bitcoin
59,693.07
(
0.97%
)
Post# of 251692
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 68
Posts 4505
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: mcbio post# 174892

Monday, 03/03/2014 7:48:39 PM

Monday, March 03, 2014 7:48:39 PM

Post# of 251692
I wouldn't read JAK1 failure in lupus into psoriasis that much as there was POC clinical data from INCY's JAK1 specifically for psoriasis. Not sure about UC study hold though as there was POC clinical data from PFE's pan-JAK tofacitinib in UC - currently in ph3. Lupus still is a tough indication, as far as I know, this would have been the first POC clinical data in lupus if successful.
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up